Major shareholders: Exelixis, Inc.

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
10.31 %
29,429,252 10.31 % 976 M $
BlackRock Advisors LLC
9.994 %
28,540,274 9.994 % 946 M $
Farallon Capital Management LLC
8.208 %
23,439,500 8.208 % 777 M $
Renaissance Technologies LLC
5.356 %
15,295,865 5.356 % 507 M $
State Street Corp.
3.996 %
11,411,943 3.996 % 378 M $
LSV Asset Management
2.861 %
8,169,847 2.861 % 271 M $
Fuller & Thaler Asset Management, Inc.
2.672 %
7,630,940 2.672 % 253 M $
Geode Capital Management LLC
1.806 %
5,157,809 1.806 % 171 M $
DFA Australia Ltd.
1.608 %
4,592,357 1.608 % 152 M $
Invesco Advisers, Inc.
1.392 %
3,975,241 1.392 % 132 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional77.02%
Other6.28%
State Street Corp.4%
Individuals2.63%
Swedbank AB0.33%
SEI Investments Co.0.29%
Schweizerische Nationalbank0.18%
Governments0.15%
Corebridge Financial, Inc.0.11%
Manulife Financial Corp.0.08%
Polar Capital Holdings Plc0.07%
Teton Advisors, Inc.0.02%
Hancock Whitney Corp.0.02%
Unknown8.82%

Based on 1000 largest holdings

Geographical origin of shareholders

United States 77.59%
United Kingdom 3.01%
Individuals 2.63%
Australia 1.65%
Canada 1.48%
Norway 1.04%
France 0.91%
Switzerland 0.51%
Bermuda 0.48%
Sweden 0.42%
Luxembourg 0.39%
Ireland 0.3%
Netherlands 0.19%
Germany 0.18%
Denmark 0.15%
Finland 0.05%
China 0.03%
Austria 0.03%
United Arab Emirates 0.03%
Liechtenstein 0.03%
Hong Kong 0.02%
Japan 0.02%
Singapore 0.01%
Cayman Islands 0.01%
Italy 0.01%

Based on 1000 largest holdings

Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Employees
1,147
More about the company